


=> d 11
L1 HAS NO ANSWERS
L1 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT IS UNS AT 17
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RSPEC 1
NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE

=> s 11 ful
FULL SEARCH INITIATED 17:28:05 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 5823 TO ITERATE

100.0% PROCESSED 5823 ITERATIONS 164 ANSWERS
SEARCH TIME: 00.00.01

L3 164 SEA SSS FUL L1

FILE CAPLUS	SINCE FILE	TOTAL
COST IN U.S. DOLLARS	ENTRY	SESSION
FULL ESTIMATED COST	148.95	149.16

FILE 'CAPLUS' ENTERED AT 17:28:10 ON 28 JAN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 28 Jan 2003 VOL 138 ISS 5
FILE LAST UPDATED: 27 Jan 2003 (20030127/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 13

L4 6 L3

=> d bib 1-6

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS
AN 2002:964343 CAPLUS
DN 138:29109
TI Preparation of crystal forms of antithrombotic piperazine derivative
IN Engel, Gary Lowell; Diseroad, Benjamin Alan
PA Eli Lilly and Company, USA
SO PCT Int. Appl., 19 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 13

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002100847	A2	20021219	WO 2002-US16569	20020606
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	WO 2001096323	A1	20011220	WO 2001-GB2553	20010612
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRAI	WO 2001-GB2553	W	20010612		
	US 2001-339295P	P	20011212		
	WO 2000-GB2302	W	20000613		
	GB 2000-30304	A	20001213		
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI WO 2001096323 A1 20011220 WO 2001-GB2553 20010612
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
 RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,
 UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 WO 2000076971 A2 20001221 WO 2000-GB2302 20000613
 WO 2000076971 A3 20010802
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,
 CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
 ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
 LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD,
 SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU,
 ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
 CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 WO 2002100847 A2 20021219 WO 2002-US16569 20020606
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
 TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI WO 2000-GB2302 W 20000613
 GB 2000-30304 A 20001213
 GB 1999-13823 A 19990614
 US 1999-142064P P 19990702
 GB 1999-18741 A 19990809
 GB 1999-29553 A 19991214
 WO 2001-GB2553 W 20010612
 US 2001-339295P P 20011212

OS MARPAT 136:54020

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS
 AN 2001:923766 CAPLUS
 DN 136:54019
 TI Preparation of amino acid derivatives as serine protease inhibitors
 IN Liebeschuetz, John Walter; Murray, Christopher William; Young, Stephen
 Clinton; Camp, Nicholas Paul; Jones, Stuart Donald; Wylie, William
 Alexander; Masters, John Joseph; Wiley, Michael Robert; Sheehan, Scott
 Martin; Engel, David Birenbaum; Watson, Brian Morgan
 PA Eli Lilly and Company, USA
 SO PCT Int. Appl., 120. pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 13

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----
PI WO 2001096304	A1	20011220	WO 2001-GB2572	20010612
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
 RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,
 UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 WO 2000076971 A2 20001221 WO 2000-GB2302 20000613
 WO 2000076971 A3 20010802
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,
 CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
 ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
 LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD,
 SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU,
 ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
 CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2002151724 A1 20021017 US 2002-30186 20020204

PRAI WO 2000-GB2302 W 20000613
 GB 2000-30306 A 20001213
 GB 1999-13823 A 19990614
 US 1999-142064P P 19990702
 GB 1999-18741 A 19990809
 GB 1999-29553 A 19991214
 WO 2001-GB2572 W 20010612

OS MARPAT 136:54019

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS
AN 2001:923758 CAPLUS

DN 136:37946

TI Preparation of amino acid derivatives as serine protease inhibitors
IN Liebeschuetz, John Walter; Murray, Christopher William; Young, Stephen
Clinton; Camp, Nicholas Paul; Jones, Stuart Donald; Wylie, William
Alexander; Masters, John Joseph; Wiley, Michael Robert; Sheehan, Scott
Martin; Engel, David Birenbaum; Watson, Brian Morgan

PA Eli Lilly and Company, USA

SO PCT Int. Appl., 142 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 13

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001096296	A1	20011220	WO 2001-GB2541	20010612
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	WO 2000076971	A2	20001221	WO 2000-GB2302	20000613
	WO 2000076971	A3	20010802		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU,				

ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI WO 2000-GB2302 W 20000613
GB 2000-30303 A 20001213
GB 1999-13823 A 19990614
US 1999-142064P P 19990702
GB 1999-18741 A 19990809
GB 1999-29553 A 19991214

OS MARPAT 136:37946

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2003 ACS

AN 2000:900614 CAPLUS

DN 134:56958

TI Preparation of amino acid derivatives as serine protease inhibitors
IN Liebeschuetz, John Walter; Lyons, Amanda Jane; Murray, Christopher
William; Rimmer, Andrew David; Young, Stephen Clinton; Camp, Nicholas
Paul; Jones, Stuart Donald; Morgan, Phillip John; Richards, Simon James;
Wylie, William Alexander; Masters, John Joseph; Wiley, Michael Robert

PA Eli Lilly and Company, USA; Protherics Molecular Design Limited

SO PCT Int. Appl., 261 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 13

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000076971	A2	20001221	WO 2000-GB2302	20000613
	WO 2000076971	A3	20010802		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1192132	A2	20020403	EP 2000-938916	20000613
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2003502314	T2	20030121	JP 2001-503831	20000613
	WO 2001096296	A1	20011220	WO 2001-GB2541	20010612
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	WO 2001096303	A1	20011220	WO 2001-GB2551	20010612
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				

DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

WO 2001096323 A1 20011220 WO 2001-GB2553 20010612

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,
UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

WO 2001096304 A1 20011220 WO 2001-GB2572 20010612

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,
UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2002151724 A1 20021017 US 2002-30186 20020204

PRAI GB 1999-13823 A 19990614
US 1999-142064P P 19990702
GB 1999-18741 A 19990809
GB 1999-29553 A 19991214
WO 2000-GB2302 W 20000613
GB 2000-30303 A 20001213
GB 2000-30304 A 20001213
GB 2000-30305 A 20001213
GB 2000-30306 A 20001213
WO 2001-GB2572 W 20010612

OS MARPAT 134:56958

L4 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2003 ACS

AN 2000:900613 CAPLUS

DN 134:56957

TI Preparation of amino acid derivatives as serine protease inhibitors
IN Liebeschuetz, John Walter; Lyons, Amanda Jane; Murray, Christopher
William; Rimmer, Andrew David; Young, Stephen Clinton; Camp, Nicholas
Paul; Jones, Stuart Donald; Morgan, Phillip John; Richards, Simon James;
Wylie, William Alexander; Lively, Sarah Elizabeth; Harrison, Martin James;
Waszkowycz, Bohdan; Masters, John Joseph; Wiley, Michael John

PA Eli Lilly and Company, USA; Protherics Molecular Design Limited

SO PCT Int. Appl., 350 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 13

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000076970	A2	20001221	WO 2000-GB2296	20000613
	WO 2000076970	A3	20010719		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,
CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD,
SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU,
ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1192135 A2 20020403 EP 2000-938912 20000613
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO
PRAI GB 1999-13823 A 19990614
US 1999-142064P P 19990702
GB 1999-18741 A 19990809
GB 1999-29552 A 19991214
GB 1999-29553 A 19991214
WO 2000-GB2296 W 20000613
OS MARPAT 134:56957


(FILE 'HOME' ENTERED AT 17:12:49 ON 28 JAN 2003)

FILE 'CAPLUS' ENTERED AT 17:12:57 ON 28 JAN 2003

L1 1 S (SERINE(L) PROTEASE) (L) (INDOL?(L) PIPERIDIN?)
L2 0 S RDG(L) (INDOL?(L) PIPERIDIN?)
L3 39 S (?COAGULA? OR ?THROMBO? OR AGGREGA?) (L) (INDOL?(L) PIPERIDIN?)
L4 29 S L3 AND PY<2000
L5 14 S L4 AND P/DT
L6 15 S L4 NOT L5

AN 1986:5787 CAPLUS
 DN 104:5787
 TI 3-Indolecarboxamide compounds
 IN Tahara, Tetsuya; Ikebe, Tsuguo; Maruyama, Yutaka; Yaoka, Osamu; Miura, Yohji
 PA Yoshitomi Pharmaceutical Industries, Ltd. , Japan
 SO Eur. Pat. Appl., 24 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 150505	A2	19850807	EP 1984-116372	19841227 <--
	EP 150505	A3	19850821		
	EP 150505	B1	19870401		
	R: AT, BE, CH, DE, FR, GB, IT, LI, NL, SE				
	JP 60142981	A2	19850729	JP 1983-251149	19831228 <--
	JP 64000396	B4	19890106		
	US 4581355	A	19860408	US 1984-680727	19841212 <--
	CA 1230600	A1	19871222	CA 1984-470179	19841214 <--
	ES 539123	A1	19860316	ES 1984-539123	19841227 <--
	AT 26273	E	19870415	AT 1984-116372	19841227 <--
PRAI	JP 1983-251149		19831228		
	EP 1984-116372		19841227		
OS	CASREACT	104:5787			
GI					




AB N-Heterocyclindolecarboxamides I (R1,R4,R6 = H, alkyl; R2,R3 = H, alkyl, alkoxy, alkanoyloxy, OH, halo; R5 = H, halo, Z = O, S, bond; n = 1,2; m, k = 1-3) were prep'd. Thus, 5-acetoxy-2-methylindole-3-carboxylic acid was converted to its acid chloride and treated with 4-amino-1-phenethylpiperidine to give carboxamide II (R7 = Ac). This was saponified to give II (R7 = OH) (III). III inhibits 5-lipoxygenase with an IC50 of 0.44 μM and I are more effective cardiotonics than ouabain.

AN 1998:534886 CAPLUS
 DN 129:148913
 TI Preparation of 5-[(4-piperidinyl)methoxy]-2-indolecarbonyl-2(S)-phenylsulfonylamino-.beta.-alanine as a fibrinogen receptor antagonist
 IN Hutchinson, John H.; Halczenko, Wasyl
 PA Merck and Co., Inc., USA
 SO U.S., 10 pp.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5789421	A	19980804	US 1996-735844	19961023 <--
PRAI US 1996-735844		19961023		

GI



AB The title compd. 5-[(4-piperidinyl)methoxy]-2-indolecarbonyl-2(S)-phenylsulfonylamino-.beta.-alanine (I) was prep'd. and formulated. The compd. is useful in inhibiting the binding of fibrinogen to blood platelets, inhibiting the aggregation of blood platelets, or treating or preventing thrombus or embolus formation. Thus, 5-hydroxyindole-2-carboxylic acid was converted to the Me ester, which underwent Mitsunobu etherification with N-Boc-4-piperidinylmethanol (DEAD, PPh₃, in THF), followed by partial hydrolysis using LiOH.H₂O, to give 5-[(4-N-Boc-piperidinyl)methoxy]-2-indolecarboxylic acid. This was condensed with Et 2(S)-[(phenylsulfonyl)amino]-3-aminopropionate.HCl in the presence of HOBT, NMM, and EDC in DMF, followed by deesterification and removal of the BOC group, to give I. In a platelet aggregation test in monkeys, I was nearly twice as potent as the analog with a piperidinylethoxy group instead of a piperidinylmethoxy group.


RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2003 ACS
 AN 1997:389217 CAPLUS
 DN 127:5015
 TI Preparation of 5-[(4-piperidinyl)methoxy]-2-indolecarbonyl-2(S)-phenylsulfonylamino-.beta.-alanine as fibrinogen receptor antagonist
 IN Hutchinson, John H.; Halczenko, Wasyl
 PA Merck and Co., Inc., USA; Hutchinson, John H.; Halczenko, Wasyl
 SO PCT Int. Appl., 33 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

PI	WO 9715568	A1	19970501	WO 1996-US16882	19961022	<--
	W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
	CA 2233861	AA	19970501	CA 1996-2233861	19961022	<--
	AU 9674640	A1	19970515	AU 1996-74640	19961022	<--
	AU 702025	B2	19990211			
	EP 863893	A1	19980916	EP 1996-936810	19961022	<--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI					
	JP 11513980	T2	19991130	JP 1996-516710	19961022	<--
	ZA 9608939	A	19970429	ZA 1996-8939	19961024	<--
PRAI	US 1995-5890P	P	19951026			
	GB 1996-3245	A	19960216			
	WO 1996-US16882	W	19961022			

GI



AB 5-[(4-Piperidinyl)methoxy]-2-indolecarbonyl-2(S)-phenylsulfonylamino-.beta.-alanine (I), useful in inhibiting the binding of fibrinogen to blood platelets, inhibiting the aggregation of blood platelets, treating thrombus formation or embolus formation, or preventing thrombus or embolus formation in a mammal, was prep'd. and formulated. Thus, esterification of 5-hydroxyindole-2-carboxylic acid followed by reaction of the resulting Me ester with N-Boc-4-piperidinylmethanol in the presence of DEAD and PPh₃ in THF, hydrolysis of the intermediate with LiOH.H₂O, reaction of 5-[(4-N-Boc-piperidinyl)methoxy]-2-indolecarboxylic acid with Et 2(S)-phenylsulfonylamino-3-aminopropionate.HCl in the presence of HOBT, NMM and EDC in DMF, deesterification and removal of the BOC group afforded I which is effective at 0.005-10 mg/kg/day.